Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Hakim Website

Frances T. Hakim, Ph.D.

Selected Publications

1)  Lee-Chang C, Bodogai M, Moritoh K, Olkhanud PB, Chan AC, Croft M, Mattison JA, Holst PJ, Gress RE, Ferrucci L, Hakim F, Biragyn A.
Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity.
Blood. [Epub ahead of print], 2014.
2)  Imanguli MM, Cowen EW, Rose J, Dhamala S, Swaim W, Lafond S, Yagi B, Gress RE, Pavletic SZ, Hakim FT.
Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease.
Leukemia. [Epub ahead of print], 2014.
3)  Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT, Kochenderfer JN.
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma.
Clin. Cancer Res. 19: 2048-60, 2013.
4)  Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA.
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
Blood. 122: 4129-39, 2013.
5)  Salit RB, Fowler DH, Dean RM, Pavletic SZ, Hakim FT, Steinberg SM, Hardy NT, Sportes C, Gress RE, Bishop MR.
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
Biol. Blood Marrow Transplant. 19: 1509-13, 2013.
6)  Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, Leitman SF, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR.
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
Blood. 121: 2864-74, 2013.
7)  Grkovic L, Baird K, Steinberg SM, Williams KM, Pulanic D, Cowen EW, Mitchell SA, Hakim FT, Martires KJ, Avila DN, Taylor TN, Salit RB, Rowley SD, Zhang D, Fowler DH, Bishop MR, Gress RE, Pavletic SZ.
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity.
Leukemia. 26: 633-43, 2012.
8)  Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR.
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
Blood. 119: 2956-9, 2012.
9)  Salit RB, Fowler DH, Wilson WH, Dean RM, Pavletic SZ, Dunleavy K, Hakim F, Fry TJ, Steinberg SM, Hughes TE, Odom J, Bryant K, Gress RE, Bishop MR.
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
J. Clin. Oncol. 30: 830-6, 2012.
10)  Fassil H, Bassim CW, Mays J, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Hakim FT, Taylor T, Avila D, Zhang D, Grkovic L, Datiles M, Gress RE, Pavletic SZ.
Oral chronic graft-vs.-host disease characterization using the NIH scale.
J. Dent. Res. 91: 45S-51S, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 8/4/2014.